
## Alice Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9321124/publications.pdf Version: 2024-02-01



ALICE WANC

#	Article	IF	CITATIONS
1	Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions. Scientific Reports, 2022, 12, 55.	3.3	9
2	Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis. Scientific Reports, 2021, 11, 14905.	3.3	1
3	Selenium Supplementation and Prostate Health in a New Zealand Cohort. Nutrients, 2020, 12, 2.	4.1	26
4	Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand. PLoS ONE, 2019, 14, e0217373.	2.5	5
5	Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts. PLoS ONE, 2018, 13, e0199122.	2.5	5
6	Environmental factors and risk of aggressive prostate cancer among a population of New Zealand men – a genotypic approach. Molecular BioSystems, 2017, 13, 681-698.	2.9	14
7	Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study. Clinical Medicine Insights: Oncology, 2017, 11, 117955491773344.	1.3	16
8	Prostate Cancer: Is It a Battle Lost to Age?. Geriatrics (Switzerland), 2016, 1, 27.	1.7	11
9	Are We Eating Our Way to Prostate Cancer—A Hypothesis Based on the Evolution, Bioaccumulation, and Interspecific Transfer of miR-150. Non-coding RNA, 2016, 2, 2.	2.6	4
10	Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?. BMC Urology, 2016, 16, 48.	1.4	16